Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment

Bone Marrow Transplantation volume 55, pages 117–125 (2020)Cite this article

Subjects

Abstract

Allogeneic stem cell transplant (alloSCT) is a current treatment option for patients with refractory/relapsed classic Hodgkin lymphoma (CHL), including those who have failed an autologous transplantation. We performed a retrospective multicenter analysis of 113 patients (median age 28 years; range 14–56; 54% males) with refractory/relapsed (R/R) CHL who had undergone alloSCT in Argentina. Kaplan–Meier was used to estimate overall (OS) and progression-free survival (PFS). Relapse rate (RR) and non-relapse mortality (NRM) were estimated with cumulative incidence analysis. Disease status at transplant was complete remission (CR) in 39%, partial remission (PR) in 44%, and stable/progressed disease (S/PD) in 17% of the patients. Donor type was matched related (MRD) in 60%, unrelated (URD) in 19%, and haploidentical (HID) in 21% of the patients. OS and PFS at 2 years were 43% and 27%, respectively, for all the cohort. In the univariate analysis, patients in CR showed better OS (p ≤ 0.001) and PFS (p ≤ 0.001), and lower NRM (p = 0.04). HID had better PFS (p = 0.04) and lower RR (p = 0.02). In the multivariate analysis, CR showed a significant impact on OS and PFS, and HID on PFS. AlloSCT is a feasible procedure in patients with CHL. Those in CR at the time of the transplant had better outcomes. Haploidentical transplantation is associated with better PFS in these patients with poor prognosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ansell SM. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:771–9.

    CAS  PubMed  Google Scholar 

  2. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet. 1993;341:1051–4.

    CAS  PubMed  Google Scholar 

  3. Duarte RF, Labopin M, Bader P et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019. https://doi.org/10.1038/s41409-019-0516-2.

    PubMed  Google Scholar 

  4. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(Nov):1812–21.

    CAS  PubMed  Google Scholar 

  5. Younes A, Santoro A, Engert A, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Armand P, Shipp MA, Moskowitz CH, Michot JM, ZinzaniPL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Collins GP, Pocock C, Peggs KS, Kayani I, Sureda A, Illidge T, et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol. 2014;164:39–52.

    PubMed  Google Scholar 

  8. Moskowitz CH. Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv. 2018;10:821–4.

    Google Scholar 

  9. Peggs KS. Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv. 2018;2:817–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Español de Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310–7.

    PubMed  PubMed Central  Google Scholar 

  11. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, et al. Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol. 2001;19:4314–21.

    CAS  PubMed  Google Scholar 

  12. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus-Hodgkin’s- lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365:1934–41.

    PubMed  Google Scholar 

  13. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transpl. 2008;14:1279–87.

    Google Scholar 

  14. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol. 2011;29:971–8.

    CAS  PubMed  Google Scholar 

  15. Greaves PJ, Gribben JG. Demonstration of durable graft versus lymphoma effects in Hodgkin’s lymphoma. J Clin Oncol. 2011;29:952.

    PubMed  Google Scholar 

  16. Raiola A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantion cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–22.

    CAS  PubMed  Google Scholar 

  17. Raiola A, Dominietto A, Bramanti S, Ghiso A, Galaverna F, Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transpl. 2014;49:190–4.

    CAS  Google Scholar 

  18. Messer M, Steinzen A, Vervölgyi E, Lerch C, Richter B, Dreger P, et al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review. Leuk Lymphoma. 2014;55:296–306.

    CAS  PubMed  Google Scholar 

  19. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.

    CAS  PubMed  Google Scholar 

  20. Pitombeira de Lacerda M, Arrais Rodrigues C, Pereira AD, Novis Y, Fonseca M, Rocha V, et al. Hla-Haploidentical transplantation for relapsed/refractory hodgkin lymphoma: a multicenter analysis. Biol Blood Marrow Transpl. 2017;23:705–70.

    CAS  Google Scholar 

  21. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14:572–8.

    CAS  PubMed  Google Scholar 

  22. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patient with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291–6.

    CAS  PubMed  Google Scholar 

  23. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin lymphoma: an analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455–62.

    CAS  PubMed  Google Scholar 

  24. Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2016;27:2251–7.

    CAS  PubMed  Google Scholar 

  25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    PubMed  Google Scholar 

  26. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.

    Google Scholar 

  27. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117:4208–17.

    CAS  PubMed  Google Scholar 

  28. Hertzberg. Mark. Relapsed/refractory Hodgkin lymphoma what is the best salvage therapy and do we need RIC-AlloSCT? Hematol Oncol Clin N Am. 2014;28:123–47.

    Google Scholar 

  29. Corradini P. Allogeneic transplantation for Hodgkin’s lymphoma. Br J Haematol. 2011;152:261–72.

    PubMed  Google Scholar 

  30. Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185–95.

    Google Scholar 

  31. Perales MA, Cebeiro I, Carpenter PA, Burns LJ, Chen R, Cole PD, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:971–83.

    Google Scholar 

  32. Hope R, Advani R, et al. NCCN. National Comprehensive Cancer Network clinical guidelines on oncology. Hodgkin lymphoma. (v2.2019). https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf.

  33. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Chen R, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Garciaz S, Coso D, Peyrade F, Fürst S, Duran S, Chetaille B, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin lymphoma. Hematol Oncol. 2014;32:187–91.

    CAS  PubMed  Google Scholar 

  35. Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz, Ramchandren R, et al. Allegeneic transplant following Brentuximab Vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic Large cell. Leuk Lymphoma. 2014;10:1–34.

    Google Scholar 

  36. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230–8.

    PubMed  Google Scholar 

  37. Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2013;98:1467–75.

    PubMed  PubMed Central  Google Scholar 

  38. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93:257–64.

    CAS  PubMed  Google Scholar 

  39. Chen R, Gopal A, Younes A, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Chen R, Palmer JM, Tsai NC, Thomas S, Paris T, Popplewell L, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transpl. 2014;20:1864–8.

    CAS  Google Scholar 

  41. Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471–8.

    CAS  PubMed  Google Scholar 

  42. Ijaz A, Khan A, Malik S, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transpl. 2019;25(Jan):94–9.

    CAS  Google Scholar 

  43. Marrioti J, Devillier R, Bramanti S, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transpl. 2018;24:627–32.

    Google Scholar 

  44. Gauthier J, Poiré X, Gac AC, et al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl. 2018;53:400–9.

    CAS  Google Scholar 

  45. Martinez C, Gayoso J, Canals C. et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425–32.

    PubMed  Google Scholar 

  46. Ahmed S, Kanakry J, Ahn K, et al. Lower GVHD and relapse risk in PTCy-based haploidentical vs matched sibling donor RIC transplant for Hodgkin lymphoma. Biology of Blood and Marrow Transplantation. 2019. https://doi.org/10.1016/j.bbmt. 2019. 05.025.

Download references

Author information

Authors and Affiliations

  1. Hospital Universitario Austral, Buenos Aires, Argentina

    María Marta Rivas, Mariano Berro & Gustavo Kusminsky

  2. Hospital Italiano de La Plata, Buenos Aires, Argentina

    María Virginia Prates, Sebastián Yantorno & Lorena Fiad

  3. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Jorge Alberto Arbelbide, Ana Lisa Basquiera & Gonzalo Ariel Ferini

  4. Hospital Privado de Córdoba, Córdoba, Argentina

    Juan José García & Pablo Andrés García

  5. Sanatorio Allende, Córdoba, Argentina

    Leandro Riera

  6. Cetramor, Rosario, Argentina

    Gustavo Jarchum

  7. Hospital Alemán de Buenos Aires, Buenos Aires, Argentina

    Alfredo Baso

  8. Sanatorio Anchorena, Buenos Aires, Argentina

    Juan Real

  9. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Martín Castro

  10. Fundación Favaloro, Buenos Aires, Argentina

    Gregorio Jaimovich

  11. Fundaleu, Buenos Aires, Argentina

    Juliana Martinez Rolón

  12. Instituto A. Flemming, Buenos Aires, Argentina

    Cecilia Foncuberta

  13. Hospital Rossi de La Plata, La Plata, Argentina

    Silvia Saba

Authors
  1. María Marta Rivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariano Berro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María Virginia Prates
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sebastián Yantorno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lorena Fiad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jorge Alberto Arbelbide
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ana Lisa Basquiera
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gonzalo Ariel Ferini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Juan José García
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pablo Andrés García
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Leandro Riera
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gustavo Jarchum
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Alfredo Baso
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Juan Real
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Martín Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Gregorio Jaimovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Juliana Martinez Rolón
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Cecilia Foncuberta
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Silvia Saba
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Gustavo Kusminsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of GATMO (Grupo Argentino de Trasplante de Médula Ósea)

Corresponding author

Correspondence to María Marta Rivas.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rivas, M.M., Berro, M., Prates, M.V. et al. Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transplant 55, 117–125 (2020). https://doi.org/10.1038/s41409-019-0640-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0640-z

This article is cited by

Search

Advanced search

Quick links